Quantcast
Last updated on April 18, 2014 at 9:32 EDT

Latest U.S. Army Medical Research and Materiel Command Stories

2013-11-05 16:27:11

REDWOOD CITY, Calif., Nov. 5, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and nine months ended September 30, 2013. "With the submission of our NDA at the end of September for Zalviso(TM), AcelRx has commenced activities related to an anticipated U.S. commercial...

2013-04-17 08:30:01

AUSTIN, Texas, April 17, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, announced the signing of a cooperative research and development agreement (CRADA) with the U.S. Army Medical Research and Materiel Command (USAMRMC). The agreement kicks off a project titled, "Cost Reduction Using OVA1 in a Treatment Algorithm for Adnexal Masses in Women," and follows a January 2012 decision by the U.S. Department...

2013-03-12 16:24:05

REDWOOD CITY, Calif., March 12, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2012, and provided a corporate update. (Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO) "We made important strides in the...

2013-02-07 12:21:01

An international collaboration of researchers from the U.S. Army Medical Research and Materiel Command (USAMRMC), Tunisia and France has demonstrated a high cure rate and remarkably few side effects in treating patients with cutaneous leishmaniasis (CL) with an investigational antibiotic cream. CL is a parasitic disease that causes disfiguring lesions, with 350 million people at risk worldwide and 1.5 million new cases annually, including U.S. military personnel serving abroad and the...

2012-11-06 16:28:34

REDWOOD CITY, Calif., Nov. 6, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and nine months ended September 30, 2012 and provided a corporate update. Net loss for the third quarter of 2012 was $8.6 million, or $0.38 per share, compared with a net loss of $5.8 million,...

2012-11-05 08:31:44

REDWOOD CITY, Calif., Nov. 5, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has dosed the first subjects in a Phase 2, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate. This study will enroll approximately 100 patients following bunionectomy...

2012-04-16 23:00:57

The Army Medical Command in conjunction with their Partnership Intermediate TEDCO, have begun an Open Innovation pilot with MMC Productions Inc of Chapel Hill to inform and encourage investors, companies and entrepreneurs to explore the USAMRMC´s extensive portfolio of available technologies. Fort Detrick, MD (PRWEB) April 15, 2012 The U.S. Army Medical Research and Materiel Command, has been on the forefront of medical discoveries for decades. There are many promising research...